Sharmila Giri

Myeloablative versus non-myeloablative consolidative chemotherapy for newly diagnosed primary central nervous system lymphoma: Results of CALGB 51101 (Alliance).

Tracy T. Batchelor, Sharmila Giri, Amy S. Ruppert et al. · Journal of Clinical Oncology · 2021 · 29 citations

Medicine, Oncology, Chemotherapy +14

Randomized Phase II/III Study of DA-EPOCH-R +/- Venetoclax in Previously Untreated Double Hit Lymphoma: Initial Results from Alliance A051701

Jeremy S. Abramson, Amy S. Ruppert, Sharmila Giri et al. · Blood · 2021 · 26 citations

Medicine, Oncology, Hematologic Oncology +4

Myeloablative vs nonmyeloablative consolidation for primary central nervous system lymphoma: results of Alliance 51101

Tracy T. Batchelor, Sharmila Giri, Amy S. Ruppert et al. · Blood Advances · 2024 · 24 citations · Full text

Medicine, Oncology, Radiation Oncology +13

Initial results of a phase II trial of 18F-DOPA PET-guided re-irradiation for recurrent high-grade glioma

William G. Breen, Ryan S. Youland, Sharmila Giri et al. · Journal of Neuro-Oncology · 2022 · 20 citations

Medicine, Nuclear Medicine, Oncology +14

Biomarkers for Risk Stratification in Patients With Previously Untreated Follicular Lymphoma Receiving Anti–CD20-based Biological Therapy

Aliyah R. Sohani, Matthew J. Maurer, Sharmila Giri et al. · The American Journal of Surgical Pathology · 2020 · 17 citations · Full text

Medicine, Immunology, Oncology +17